Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?

Nat Rev Rheumatol. 2017 Jan 25;13(2):76-78. doi: 10.1038/nrrheum.2016.224.

Authors

Nancy E Lane¹, Maripat Corr²

Affiliations

¹ Center for Musculoskeletal Health, Department of Medicine, University of California at Davis School of Medicine, 4625 2nd Avenue, Sacramento, California 95817, USA.
² Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, California 92093-0663, USA.

PMID: 28119540
DOI: 10.1038/nrrheum.2016.224

No abstract available

MeSH terms

Analgesics, Non-Narcotic / adverse effects*
Analgesics, Non-Narcotic / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Arthralgia / drug therapy
Arthralgia / etiology
Chronic Pain
Humans
Musculoskeletal Pain / drug therapy*
Musculoskeletal Pain / etiology
Nerve Growth Factor / antagonists & inhibitors*
Nerve Growth Factor / metabolism
Osteoarthritis / complications*

Substances

Analgesics, Non-Narcotic
Antibodies, Monoclonal, Humanized
fasinumab
Nerve Growth Factor
tanezumab